| Title |
Advances in Clinical Cardiology
|
|---|---|
| Published in |
Advances in Therapy, July 2014
|
| DOI | 10.1007/s12325-014-0141-9 |
| Pubmed ID | |
| Authors |
Andrew H. McNeice, Neil M. McAleavey, Ian B. A. Menown |
| Abstract |
Multiple, potentially practice-changing cardiology trials have been presented or published over the past year. In this paper, we summarize and place in clinical context, new data regarding management of acute coronary syndrome and ST-elevation myocardial infarction (copeptin assessment, otamixaban, cangrelor, prasugrel, sodium nitrite, inclacumab, ranolazine, preventive coronary intervention of non-culprit lesions, immediate thrombolytic therapy versus transfer for primary intervention), new coronary intervention data (thrombectomy, radial access, pressure wire fractional flow reserve, antiplatelet therapy duration and gene-guidance, permanent and biodegradable polymers, coronary bifurcation and strategies), and coronary artery bypass data (off pump vs. on pump). Latest trials in trans-aortic valve implantation, heart failure (eplerenone, aliskiren, spironolactone, sildenafil, dopamine, nesiritide, omecamtiv mecarbil, the algisyl left ventricular augmentation device, and echo-guided cardiac resynchronization), atrial fibrillation (edoxaban, dabigatran, and ablation), cardiac arrest (hypothermia, LUCAS™ mechanical chest compression), and cardiovascular prevention (vitamins, renal denervation for resistant hypertension, renal artery stenting, saxagliptin, alogliptin, and gastric banding) are also discussed. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Slovenia | 1 | <1% |
| Unknown | 125 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 22 | 17% |
| Student > Bachelor | 17 | 13% |
| Researcher | 16 | 13% |
| Student > Ph. D. Student | 12 | 10% |
| Student > Postgraduate | 9 | 7% |
| Other | 20 | 16% |
| Unknown | 30 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 69 | 55% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Nursing and Health Professions | 5 | 4% |
| Agricultural and Biological Sciences | 2 | 2% |
| Sports and Recreations | 2 | 2% |
| Other | 6 | 5% |
| Unknown | 37 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2014.
All research outputs
#12,785,987
of 22,764,165 outputs
Outputs from Advances in Therapy
#854
of 2,337 outputs
Outputs of similar age
#101,896
of 228,689 outputs
Outputs of similar age from Advances in Therapy
#7
of 24 outputs
Altmetric has tracked 22,764,165 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,337 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,689 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.